A Multicenter Treatment Protocol for Expanded Access Use of Ipilimumab (BMS-734016) Monotherapy in Subjects With Unresectable Stage III or Stage IV Melanoma

Trial Profile

A Multicenter Treatment Protocol for Expanded Access Use of Ipilimumab (BMS-734016) Monotherapy in Subjects With Unresectable Stage III or Stage IV Melanoma

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Dec 2015

At a glance

  • Drugs Ipilimumab (Primary)
  • Indications Malignant melanoma
  • Focus Expanded access; Therapeutic Use
  • Acronyms IMEXA
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 01 Dec 2015 Results related to immunoregulatory predictors of efficacy from NCT00094653 and NCT00495066 published in the Cancer Research
    • 31 May 2013 Status changed from recruiting to completed (expanded access is no longer available), according to ClinicalTrials.gov record.
    • 19 Feb 2013 New source identified and integrated: Mayo Clinic record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top